Literature DB >> 27802400

Revised Discriminating Lethal Doses For Resistance Monitoring Program on Aedes albopictus Against Temephos and Malathion in Penang Island, Malaysia.

Junaid Rahim, Abu H Ahmad, Nur Faeza A Kassim, Hamdan Ahmad, Intan H Ishak, Adanan Che Rus, Hamisu A Maimusa.   

Abstract

Dengue vector control still heavily relies on the use of chemical insecticides, and the widespread use of insecticides has led to resistance in mosquitoes. The diagnostic dose is a key part of resistance monitoring. The present study corroborates the discriminating lethal doses of temephos and malathion based on dose-response of known susceptible strain of Aedes albopictus following the World Health Organization (WHO) diagnostic test procedure. Late 3rd and early 4th instars were tested with a range of larvicides to determine the lethal concentrations (LC50 and LC99) values. A slightly higher diagnostic dose of 0.020 mg/liter as compared with the WHO-established value of 0.012 mg/liter was observed for temephos. Meanwhile, a malathion diagnostic dose of 0.200 mg/liter is also reported here since there are no such reported values by WHO. Doubling the LC99 values of susceptible strains, 3 of the 5 wild-collected populations showed resistance to temephos and 2 showed incipient resistance; all 5 populations showed incipient resistance to malathion. The revised and established lethal diagnostic dose findings from the current work are crucial to elaborate on the variation in susceptibility of Ae. albopictus in future resistance monitoring programs in Malaysia.

Entities:  

Keywords:  Aedes albopictus; dengue; diagnostic dose; malathion; temephos

Mesh:

Substances:

Year:  2016        PMID: 27802400     DOI: 10.2987/16-6556.1

Source DB:  PubMed          Journal:  J Am Mosq Control Assoc        ISSN: 8756-971X            Impact factor:   0.917


  1 in total

1.  Insecticide resistance of Dengue vectors in South East Asia: a systematic review.

Authors:  Mohd Rohaizat Hassan; Noor Atika Azit; Suhaiza Mohd Fadzil; Siti Rasidah Abd Ghani; Norfazilah Ahmad; Azmawati Mohammed Nawi
Journal:  Afr Health Sci       Date:  2021-09       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.